Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review

Massimo Franchini1,2, Gian Luca Forni3, Giuseppe Marano1, Mario Cruciani1,4, Carlo Mengoli1, Valeria Pinto1, Lucia De Franceschi2, Donatella Venturelli6, Maddalena Casale3, Martina Amerini1,8, Martina Capuzzo9, Giuliano Grazzini1,8, Francesca Masiello1, Ilaria Pati1, Eva Veropalumbo1, Stefania Vaglio1,10, Simonetta Pupella1, Giancarlo M. Liumbruno1

1Italian National Blood Centre, National Institute of Health, Rome; 2Department of Haematology and Transfusion Medicine, "Carlo Poma" Hospital, Mantua; 3Centre for Microcythemia and Congenital Anaemia, "Galliera" Hospital, Genoa; 4Infection Control Committee and Antibiotic Stewardship Programme, AULSS9 "Scaligera", Verona; 5Department of Medicine, University of Verona and AOU-Verona, Policlinico "G.B. Rossi", Verona; 6Department of Transfusion Medicine, University Hospital of Modena, Modena; 7Department of Women, Children and General and Specialised Surgery, "Luigi Vanvitelli" University of Campania, Naples; 8Italian Foundation for Research on Anaemia (FORANEMIA) and Haemoglobinopathies, Genoa; 9Mother-Infant Department, University of Modena and Reggio Emilia, Modena; 10Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy

Abstract

Background. Chronic red blood cell transfusion is the first-line treatment for severe forms of thalassaemia. This therapy is, however, hampered by a number of adverse effects, including red blood cell alloimmunisation. The aim of this systematic review was to collect the current literature data on erythrocyte alloimmunisation.

Materials and methods. We performed a systematic search of the literature which identified 41 cohort studies involving 9,256 patients.

Results. The prevalence of erythrocyte alloimmunisation was 11.4% (95% CI: 9.3-13.9%) with a higher rate of alloimmunisation against antigens of the Rh (52.4%) and Kell (25.6%) systems. Overall, alloantibodies against antigens belonging to the Rh and Kell systems accounted for 78% of the cases. A higher prevalence of red blood cell alloimmunisation was found in patients with thalassaemia intermedia compared to that among patients with thalassaemia major (15.5 vs 12.8%).

Discussion. Matching transfusion-dependent thalassaemia patients and red blood cell units for Rh and Kell antigens should be able to reduce the risk of red blood cell alloimmunisation by about 80%.

Keywords: thalassaemia, alloimmunisation, red blood cells, transfusion, complications.

Introduction

Thalassaemia, a congenital haemolytic disorder caused by a partial or complete defect in the synthesis of α- or β-globin chains, is one of the major health issues worldwide, considering that every year 60,000 babies are born with severe forms of thalassaemia1. The primary therapy for thalassaemia major is lifelong transfusion of red blood cells (RBC), which has the aim of suppressing ineffective erythropoiesis and improving the growth and development of affected children2. However, although this treatment is life-saving, it is encumbered by a number of complications, including haemosiderosis, transfusion reactions, infections (potentially caused also by emerging or re-emerging infectious disease agents3,4, as the residual risk of transfusion-transmitted infections has consistently declined over time5), and alloimmunisation6-11. In particular, alloimmunisation is a challenging occurrence which increases the risk of delayed haemolytic transfusion reactions, complicates cross-matching and contributes to a delay in the identification and provision of compatible RBC transfusions6-11. Transfusion therapy may also be required by patients with thalassaemia intermedia in particular circumstances (growth failure, extramedullary haematopoiesis, pregnancy, infections, operations) so that a consistent proportion of such patients are at risk of developing transfusion-associated complications, including alloimmunisation12.

The purpose of this systematic review is to summarise the current literature on erythrocyte alloimmunisation in patients with transfusion-dependent thalassaemia, with the aim of improving our knowledge on the associated risk factors and optimising the approach to patients’ transfusion therapy.

Materials and methods

Search strategy

A computer-assisted literature search of the MEDLINE (through PUBMED), EMBASE, SCOPUS, OVID and Cochrane Library electronic databases was performed (latest search August 30, 2018) to identify
Red blood cell alloantibodies in thalassaemia

studies on RBC alloimmunisation in patients with transfusion-dependent thalassaemia. A combination of the following text words was used to maximise the specificity and sensitivity of the search: "red blood cells", "erythrocyte", "alloimmunization", "alloantibodies", "reactions", "thalassemia major", "thalassemia intermedia", "beta thalassemia", "β thalassemia", "transfusion", "transfusion-dependent", "patients". In addition, we checked the reference lists of the most relevant items (original studies and reviews) in order to identify potentially eligible studies not captured by the initial literature search.

**Study selection and inclusion criteria**

Studies were selected independently by two reviewers (MF and MC), with disagreements resolved through discussion and on the basis of the opinion of a third reviewer (GM). Assessment of the eligibility of studies was based on the title or abstract and on the full text, if required. Articles were eligible if they reported erythrocyte alloimmunisation in transfusion-dependent thalassaemia patients (i.e., patients with thalassaemia major or thalassaemia intermedia) in either the title or the abstract. Other required inclusion criteria were that the article be: (i) original, (ii) randomised, cohort, cross-sectional or case-control, (iii) retrospective or prospective, and (iv) published in full in English in the last 20 years (1998-2018).

**Data extraction**

For each study included in the systematic review, the following data were extracted independently by two reviewers (MF and MC): first author, year of publication, origin of the population studied, study design, sample size and disease type, median age and range, rate and type of RBC alloantibodies detected, type of test used for alloantibody detection, transfusion protocol and evaluated variables (RBC phenotype matching, sex, age at enrolment, age at first transfusion, years of transfusions, RBC units received, splenectomy, RBC leucoreduction) with the main results of the studies. Disagreement was resolved by consensus and by the opinion of a third reviewer (GM), if necessary.

**Assessment of risk of bias in the included studies**

Since no randomised controlled trials were found for this systematic review, we assessed the methodological quality of the observational studies following the recommendations from the Cochrane Handbook for Systematic Reviews of Interventions on assessing the quality of non-randomised studies. We used the Newcastle-Ottawa quality assessment scale (NOS) to assess the quality of cohort studies.

The methodological quality of cohort studies is assessed by examining selection (four questions relating to the representativeness of the cohort, selection of the unexposed cohort, ascertainment of exposure and demonstration that the outcome of interest was not present at the start of the study), comparability (exposed and unexposed individuals must be matched in the design and/or confounders must be adjusted for in the analysis) and outcome (three questions relating to the assessment of outcome, follow up long enough for outcomes to occur and losses to follow up).

These assessments were performed independently in duplicate (MC, MF) and a third reviewer (GM) resolved any disagreements to reach consensus. Using the NOS, a study can be awarded a maximum of four stars for selection, a maximum of two stars for comparability, and a maximum of three stars for outcome (Online Supplementary Content, Table S1).

**Statistical analysis**

Qualitative data are presented as numbers and percentages, while quantitative data are expressed statistically in frequencies and percentages. A mean prevalence of RBC alloantibodies was estimated by meta-analysis of the proportions method. This method is based on meta-analytical pooling of the logit-transformed prevalences at a study level. These are used to produce summary measures. The meta-analytical methods used were: the inverse variance method; DerSimonian-Laird estimator for tau²; logit transformation; Clopper-Pearson confidence interval for individual studies; and a continuity correction of 0.5 in studies with zero cell frequencies. Both fixed effects and random effects models were used. The heterogeneity between studies was assessed by the heterogeneity χ² test (Cochran's Q), the F statistics, and the DerSimonian-Laird estimate of between-study variance (τ²). When the size of the population affected by thalassaemia major or thalassaemia intermedia clinical variants was reported along with the alloantibody prevalence, the relevant information was used to perform subgroup analyses. The random effects model is reported as it is preferred in subgroup meta-analyses, or when heterogeneity tests are significant. All calculations were done using R-3.5.1 for windows.

**Results**

**Literature search and characteristics of the studies**

In total, 478 articles were identified through the initial electronic and manual searches (Figure 1). Three hundred and fifty-two of them were excluded because they focused on topics outside the scope of this systematic review. Thus, 126 potentially relevant articles were selected and the next screening led to the exclusion of 85 of these (reviews, duplicates, studies...
not evaluating patients with transfusion-dependent thalassaemia, studies containing no informative data). Finally, 41 studies were included in the systematic review (see Table I for the main characteristics and results of the studies included). The studies contained data from 9,256 individuals (children and adults) from different countries and originated in India (n=12), Iran (n=6), Egypt (n=6), Pakistan (n=3), Oman (n=3), Taiwan (n=2), Asia (n=2) and the USA, Malaysia, Tunisia, Hong Kong, Turkey, Albania, Kuwait (each with 1 study) (Table I). No studies conducted in European countries were included in this systematic review.

All the studies were classified as cohort studies. The design was retrospective in 11 studies and prospective in 17. Thirteen studies in which the investigator sampled a source population cross-sectionally and then retrospectively assessed subjects' histories of exposures and outcomes over a specified time period were defined as cross-sectional cohort studies.

The sample size of the included studies ranged from 30 patients in the study by Wang and colleagues to 835 patients in the study by Azarkeivan and colleagues. Transfusion-dependent thalassaemia was β-thalassaemia major in the majority of cases (n=4,829); patients with thalassaemia intermedia (n=491), α-thalassaemia syndromes as well as haemoglobin E/β thalassaemia (n=148) and otherwise undefined cases (n=3,788) were also included.

**Bias assessment**

We present the results of the NOS in the Online Supplementary Content, Table S1. The quality of cohort studies was assessed by examining selection, comparability and outcome. Of the 41 cohort studies included, all achieved the maximum four stars for selection, and the maximum three stars for outcome; for comparability, 39 studies achieved the maximum two stars, but two studies merited only one star because they did not control for confounders.

**Frequency of erythrocyte alloimmunisation**

Online Supplementary Table SII reports the detailed analysis of RBC alloantibodies for each study. The great majority of the studies included used high sensitivity agglutination microcolumn assays (Online Supplementary Content, Table SIII). The prevalence
Table I - Characteristics and main results of the studies included on alloimmunisation in transfusion-dependent thalassaemia.

<table>
<thead>
<tr>
<th>Study (year)ref</th>
<th>Origin</th>
<th>Study design</th>
<th>Cases (N)</th>
<th>Median age, years (range)</th>
<th>Alloantibodies</th>
<th>Transfusion policy</th>
<th>Risk factors analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Singer (2000)13</td>
<td>Asian</td>
<td>Cohort, retrospective</td>
<td>64 (30 TM; 34 others)</td>
<td>15 (2-39)</td>
<td>Anti-K (42.9); anti-Kp(^b) (7.1); anti-E (28.6); anti-C (14.3); anti-i (14.3); anti-M (7.1); anti-Jk(^b) (7.1); anti-Le(^b) (7.1)</td>
<td>ABO-D or ABO-Rh and Kell matched RBC. Bedside leucofiltered blood in 90% of patients.</td>
<td>A positive association was found between splenectomy and alloimmunisation. Transfusion of ABO-Rh-Kell matched RBC was effective in preventing alloimmunisation.</td>
</tr>
<tr>
<td>Ameen (2003)14</td>
<td>Kuwait</td>
<td>Cohort, prospective</td>
<td>190 TM</td>
<td>12.7 (0.25-33)</td>
<td>Anti-K (72); anti-E (45.6); anti-D (21.1); anti-v (21.1); anti-C (15.8); anti-Le(^a) (12.3); anti-Jk(^b) (10.5); anti-c (8.8); anti-C(^w) (8.8); anti-Kp(^b) (5.3); anti-S (5.3); anti-Jk(^a) (3.5); anti-Fy(^b) (3.5); anti-Fy(^b) (3.5); anti-Le(^b) (3.5); anti-Jk(^b) (1.8); anti-Lu(^a) (1.8); anti-C(^b) (1.8); anti-C(^w) (1.8); anti-Le(^a) (1.8); anti-E(^c) (1.8)</td>
<td>ABO-Rh matched RBC for patients with antibodies. Post-storage leucoreduction.</td>
<td></td>
</tr>
<tr>
<td>Bilwani (2005)15</td>
<td>Pakistan</td>
<td>Cohort, retrospective</td>
<td>97 TM</td>
<td>10.6 (2-24)</td>
<td>Anti-K (22); anti-D (11.1); anti-E (11.1); anti-D+C (11.1); anti-E+K (11.1)</td>
<td>ABO-D matched RBC.</td>
<td></td>
</tr>
<tr>
<td>Wang (2006)16</td>
<td>Taiwan</td>
<td>Cohort, cross-sectional</td>
<td>30 (28 TM; 2 others)</td>
<td>20 (4-31)</td>
<td>Anti-E (36); anti-E+c (18); anti-M(^p) (18); anti-M(^w)+anti-c (9); anti-D (9); anti-S (9)</td>
<td>ABO matched RBC. Bedside leucoeduction.</td>
<td></td>
</tr>
<tr>
<td>Noor Haslina (2006)17</td>
<td>Malaysia</td>
<td>Cohort, prospective</td>
<td>58 (8 TM; 50 others)</td>
<td>NA</td>
<td>Anti-E (40); anti-E+c+anti-S+anti-N (20); anti-E+anti-Jk(^a) (20); anti-K (20)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Karimi (2007)18</td>
<td>Iran</td>
<td>Cohort, cross-sectional</td>
<td>711 TDT</td>
<td>14.4 (1-41)</td>
<td>Anti-K (50); anti-D (15.8); anti-E (10.5); anti-D+C (7.9); anti-C (5.3); anti-c (5.3); anti-c (2.6); anti-Le(^b) (2.6)</td>
<td>ABO-D matched RBC. Bedside leucofiltered blood in 73% of patients.</td>
<td>A positive correlation was found between alloimmunisation and duration of blood transfusion (&gt; 6 years).</td>
</tr>
<tr>
<td>Sadeghian (2009)19</td>
<td>Iran</td>
<td>Cohort, cross-sectional</td>
<td>313 TDT</td>
<td>14.4 (0.7-38)</td>
<td>Anti-D (88.9); anti-C (33.3); anti-E (11.1)</td>
<td>ABO-D matched RBC. Bedside leucofiltered blood in a subset of patients.</td>
<td>A higher frequency of alloimmunisation was observed in female and splenectomised patients.</td>
</tr>
<tr>
<td>Ahmed (2010)20</td>
<td>Egypt</td>
<td>Cohort, prospective</td>
<td>448 (389 TM; 59 TI)</td>
<td>14 (2.2-24)</td>
<td>Anti-K (42); anti-E (24); anti-C (18); anti-Fy(^b) (6); anti-Kp(^b) (6); anti-M (3)</td>
<td>ABO-D matched RBC.</td>
<td>A positive association was found between splenectomy and alloimmunisation.</td>
</tr>
<tr>
<td>Gupta (2011)22</td>
<td>India</td>
<td>Cohort, cross-sectional</td>
<td>116 TM</td>
<td>14 (2-27)</td>
<td>11/116 (9.5)</td>
<td>ABO-D matched RBC.</td>
<td>-</td>
</tr>
<tr>
<td>Chaudhari (2011)23</td>
<td>India</td>
<td>Cohort, cross-sectional</td>
<td>32 TM</td>
<td>NA (1-18)</td>
<td>6/32 (18.8)</td>
<td>ABO-D matched RBC. Non-leucoreduced RBC.</td>
<td>-</td>
</tr>
<tr>
<td>Guirat-Dhouib (2011)24</td>
<td>Tunis</td>
<td>Cohort, prospective</td>
<td>130 TDT</td>
<td>10 (1-26)</td>
<td>10/130 (7.7)</td>
<td>ABO-D matched RBC. Non-leucoreduced RBC for the majority of patients.</td>
<td>-</td>
</tr>
</tbody>
</table>

Continued on next page.
Table I - Characteristics and main results of the studies included on alloimmunisation in transfusion-dependent thalassaemia. (continued from previous page)

<table>
<thead>
<tr>
<th>Study (year)ref</th>
<th>Origin</th>
<th>Study design</th>
<th>Cases (N)</th>
<th>Median age, years (range)</th>
<th>Allantibodies</th>
<th>Transfusion policy</th>
<th>Risk factors analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARAZKEVIN (2011)25</td>
<td>Iran</td>
<td>Cohort, prospective</td>
<td>835 (707 TM; 128 TI)</td>
<td>NA</td>
<td>Anti-K (33.7); anti-Rh (14.9); anti-D (10.9); anti-E (9.9); anti-D+anti-C (7.9); anti-K+anti-E (3); anti-K+anti-Kpa (3); anti-D+anti-E (1)</td>
<td>NA</td>
<td>The alloantibody risk was greater in patients with TI, with increasing age and more exposure to different RBC antigens.</td>
</tr>
<tr>
<td>THOMPSON (2011)26</td>
<td>USA</td>
<td>Cohort, prospective</td>
<td>697 TDT</td>
<td>NA</td>
<td>Anti-E (19); anti-K (18.1); anti-C (9.5); anti-Kidd (7.8); anti-c (6.0); anti-e (5.2); anti-Kpα (5.2); anti-Le (3.4); anti-D (3.4); anti-S (2.6); anti-Duffy (1.7); anti-M (1.7)</td>
<td>Extended phenotype-matched RBC in a minority of patients. Leucoreduced RBC.</td>
<td></td>
</tr>
<tr>
<td>SAIED (2011)27</td>
<td>Egypt</td>
<td>Cohort, retrospective</td>
<td>95 (74 TM; 21 TI)</td>
<td>17.1 (1-45)</td>
<td>27/95 (28.4)</td>
<td>Anti-Kell (23.6); anti-E (23.6); anti-C (23.6); anti-D (5.5); anti-c (5.5); anti-S (5.5); anti-Fy(a) (5.5); anti-Jka (3.6); anti-Jkb (3.6); anti-Lea (3.6); anti-Leb (3.6); anti-M (3.6); anti-N (0.9); anti-n (0.9); anti-Jka (0.9); anti-Jkb (0.9)</td>
<td>ABO-D matched RBC. Leucoreduced RBC in 67% of patients.</td>
</tr>
<tr>
<td>CHENG (2012)28</td>
<td>Hong Kong</td>
<td>Cohort, retrospective</td>
<td>382 TM</td>
<td>23 (0.25-52)</td>
<td>77/382 (20.2)</td>
<td>Anti-E (37); anti-MP/Mur (29); anti-c (12); anti-Jka (6); anti-S (1.8); anti-Di (1.8); anti-c (0.9); anti-e (0.9); anti-f (0.9); anti-K (0.9); anti-Jkb (0.9)</td>
<td>Leucoreduction within 3 days of production.</td>
</tr>
<tr>
<td>EL-DANASOURY (2012)29</td>
<td>Egypt</td>
<td>Cohort, prospective</td>
<td>235 TM</td>
<td>12 (6-34)</td>
<td>46/235 (19.5)</td>
<td>Anti-Kell (23.9); anti-E (23.9); anti-C (15.2); anti-D (13); anti-Cw (11); anti-N (6.3); anti-Hpa (4.3); anti-Kpa (2.1); anti-Lea (2.1)</td>
<td>ABO-D matched RBC.</td>
</tr>
<tr>
<td>CHAO (2013)30</td>
<td>Taiwan</td>
<td>Cohort, cross-sectional</td>
<td>64 TM</td>
<td>19.2 (+6.7)</td>
<td>6/64 (9.4)</td>
<td>Anti-E (66.6); anti-C (16.7); anti-MPa (16.7)</td>
<td>ABO-D matched RBC.</td>
</tr>
<tr>
<td>MALIK (2013)31</td>
<td>India</td>
<td>Cohort, prospective</td>
<td>462 TDT</td>
<td>NA (0.7-38)</td>
<td>19/462 (4.1)</td>
<td>Anti-K (42.1); anti-E (35.8); anti-D (5.3); anti-Cw (3.5); anti-N (3.5)</td>
<td>ABO-D matched RBC.</td>
</tr>
<tr>
<td>AL-RUYAMI (2014)32</td>
<td>Oman</td>
<td>Cohort, retrospective</td>
<td>37 TI</td>
<td>27 (11-59)</td>
<td>7/24 (29.2)</td>
<td>Anti-E (57.1); anti-c (20.8); anti-K (28.6); anti-Jka (28.6); anti-D (14.3)</td>
<td>Extended phenotype-matched RBC. Leucoreduced RBC.</td>
</tr>
<tr>
<td>DHAWAN (2014)33</td>
<td>India</td>
<td>Cohort, cross-sectional</td>
<td>319 TM</td>
<td>15.2 (1.5-27)</td>
<td>18/319 (5.6)</td>
<td>Anti-E (17); anti-D (13); anti-C (13); anti-Cw (9); anti-K (35); anti-Kidd (9); anti-Xga (4)</td>
<td>ABO-D matched RBC. Antigen matched in patients with alloantibodies.</td>
</tr>
<tr>
<td>JAIN (2014)34</td>
<td>India</td>
<td>Cohort, prospective</td>
<td>96 TM</td>
<td>NA</td>
<td>5/96 (5.2)</td>
<td>Anti-K (60); anti-E (20); anti-Kpa (20)</td>
<td>ABO-D matched RBC.</td>
</tr>
<tr>
<td>HUSSEIN (2014)35</td>
<td>Egypt</td>
<td>Cohort, retrospective</td>
<td>272 (207 TM; 65 TI)</td>
<td>NA</td>
<td>62/272 (22.8)</td>
<td>Anti-E (14.6); anti-D (8.9); anti-C (8.9); anti-c (4.9); anti-K (26); anti-MNS (9.8); anti-Kidd (8.9); anti-Duffy (8.1); anti-Le (5.7); anti-Lu (2.4); anti-P1 (1.6)</td>
<td>ABO-D matched RBC. Pre-storage leucoreduction in 40% of patients.</td>
</tr>
<tr>
<td>PHILIP (2014)36</td>
<td>India</td>
<td>Cohort, retrospective</td>
<td>82 TDT</td>
<td>NA</td>
<td>6/82 (7.3)</td>
<td>Anti-E (45); anti-D (14); anti-c (14); anti-Lea (14)</td>
<td>ABO-D matched RBC. Leucoreduced RBC.</td>
</tr>
</tbody>
</table>

Continued on next page.
Table I - Characteristics and main results of the studies included on alloimmunisation in transfusion-dependent thalassaemia. (continued from previous page)

<table>
<thead>
<tr>
<th>Study (year)ref</th>
<th>Origin</th>
<th>Study design</th>
<th>Cases (N)</th>
<th>Median age, years (range)</th>
<th>Alloantibodies</th>
<th>Transfusion policy</th>
<th>Risk factors analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koçyiğit (2014)37</td>
<td>Turkey</td>
<td>Cohort, retrospective</td>
<td>139 (109 TM; 30 TI)</td>
<td>18.3 (+8.7) 1</td>
<td>Anti-K (27); anti-C (27); anti-D (38); anti-Jka (18); anti-E (9)</td>
<td>Leucoreduced RBC.</td>
<td>The risk of alloimmunisation increased in patients with TI and in those who received a first transfusion &gt; 2 years of age.</td>
</tr>
<tr>
<td>Ellence (2014)38</td>
<td>India</td>
<td>Cohort, prospective</td>
<td>280 TM</td>
<td>10 (0.7-32) 24/280 (8.6)</td>
<td>Anti-E (39.3); anti-K (41.4); anti-c (10.8); anti-D (7.1); anti-C (7.1); anti-Jka (7.1); anti-N (5.5); anti-S (5.5)</td>
<td>ABO-D matched RBC.</td>
<td>-</td>
</tr>
<tr>
<td>Vichinsky (2014)39</td>
<td>Asian and Caucasian</td>
<td>Cohort, prospective</td>
<td>365 (278 TM; 28 TI; 59 others)</td>
<td>NA</td>
<td>Anti-E (29%; anti-K (17); anti-C (12); anti-Jka (6); anti-c (5); anti-Kp a (4); anti-D (3); anti-S (3); anti-Cw (2); anti-e (2); anti-Jkb (2); anti-Le a (2); anti-Fya (1); anti-Fyb (1); anti-Le b (1); anti-M (1)</td>
<td>ABO-D matched RBC (31%); ABO-Rh-K matched RBC (38%); extended phenotype-matched RBC (10%). Leucoreduced RBC (94%).</td>
<td>Year of transfusion was an independent predictor of alloimmunisation.</td>
</tr>
<tr>
<td>Dogra (2015)40</td>
<td>India</td>
<td>Cohort, cross-sectional</td>
<td>70 (59 TM; 8 TI; 3 others)</td>
<td>NA (2-17) 6/70 (8.6)</td>
<td>Anti-E (37.5); anti-K (25); anti-D (12.5)</td>
<td>ABO-D matched RBC.</td>
<td>-</td>
</tr>
<tr>
<td>Datta (2015)41</td>
<td>India</td>
<td>Cohort, prospective</td>
<td>500 (333 TM; 167 TI)</td>
<td>NA</td>
<td>28/500 (5.6)</td>
<td>Anti-c (28.6); anti-E (21.4); anti-c+anti-E (17.8); anti-Jka (7.1); anti-Kp a (3.6); anti-C (3.6); anti-D (3.6); anti-D+anti-E (3.6); anti-E+anti-Fya (3.6); anti-E+anti-Fyb (3.6); anti-E (3.6)</td>
<td>ABO-D matched RBC.</td>
</tr>
<tr>
<td>Jansuwan (2015)42</td>
<td>India</td>
<td>Cohort, cross-sectional</td>
<td>143 TM</td>
<td>16 (11-21) 25/143 (17.5)</td>
<td>Anti-E (52); Anti-c (16); anti-M (16); Anti-Le a (16); anti-M (16); anti-Jka (8)</td>
<td>Leucoreduced RBC.</td>
<td>Alloimmunisation correlated with splenectomy.</td>
</tr>
<tr>
<td>Seferi (2015)43</td>
<td>Albania</td>
<td>Cohort, prospective</td>
<td>118 TM</td>
<td>17 (2-34) 14/118 (11.8)</td>
<td>Anti-K (23.9); anti-D (19.1); anti-C (14.3); anti-E (14.3); anti-c (14.3); anti-c (4.7); anti-Jka (4.7); anti-Cw (4.7)</td>
<td>Post-storage leucoreduced RBC.</td>
<td>Rheas and Kell matching greatly reduced the development of new alloantibodies.</td>
</tr>
<tr>
<td>Vaziri (2015)44</td>
<td>Iran</td>
<td>Cohort, cross-sectional</td>
<td>100 TDT</td>
<td>15 (+7.9) 1</td>
<td>4/100 (4)</td>
<td>Anti-K (75); anti-D+anti-C (25)</td>
<td>Leucoreduced RBC.</td>
</tr>
<tr>
<td>Obaid (2015)45</td>
<td>Egypt</td>
<td>Cohort, prospective</td>
<td>40 (26 TM; 14 TI)</td>
<td>TM: 20.3 (+7.3) TI: 36.9 (+11.4) 17:40 (42.5)</td>
<td>Anti-Lu a (19); anti-Kpa (19); anti-Lu b (9.5); anti-Kp a (9.5); anti-D (4.8); anti-c (4.8); anti-K (4.8)</td>
<td>ABO-D matched RBC.</td>
<td>Matching RBC for Rh and Kell antigens reduced the risk of alloimmunisation by 90%.</td>
</tr>
<tr>
<td>Davari (2016)46</td>
<td>Iran</td>
<td>Cohort, cross-sectional</td>
<td>49 TM</td>
<td>18.6 (+8.16) 1</td>
<td>8/49 (16.3)</td>
<td>Anti-K (75); anti-E (12.5); anti-c (12.5); anti-Le a (12.5)</td>
<td>Leucoreduced RBC.</td>
</tr>
<tr>
<td>Abdelrazik (2016)47</td>
<td>Egypt</td>
<td>Cohort, prospective</td>
<td>188 (147 TM; 41 TI)</td>
<td>10 (2-45) 15/188 (8.0)</td>
<td>Anti-D (53); anti-E (13); anti-C (13); anti-c (13); anti-Le a (13); anti-Le b (13); anti-K (6.6)</td>
<td>Leucoreduced RBC.</td>
<td>Lower rate in patients who received leucoreduced RBC.</td>
</tr>
</tbody>
</table>

Continued on next page.
of alloantibodies in the thalassaemia patients, without distinguishing between the clinical variants, is depicted in Figure 2. As stated above, 41 studies were included. The random effects model resulted in a mean prevalence of 0.1137 (95% CI: 0.0928; 0.1386). The heterogeneity was substantial: Cochran’s Q was 427.80, with degrees of freedom (d.o.f.)=40 (p<0.0001), \( I^2=90.6\% \) (88.3%; 92.6%).

The variation of erythrocyte alloimmunisation ranged from 2.9% (Sadeghian et al.\(^{19}\)) to 37.0% (Wang et al.\(^{16}\)). Taking into account all selected studies, a higher rate of alloimmunisation against antigens of the Rh system (52.4%), especially against E antigen (22.0%), was observed, showing that these antigens are among the most immunogenic. Alloantibodies against D, C, c and e antigens accounted for 6.9%, 5.5%, 5.5% and 1.3% of the cases, respectively.

The second highest rate was found for alloantibody antigens of the Kell system (25.6%), especially against K antigen (22.5%), followed by the Kidd system (3.9%) and the MNS system (2.4%) (Online Supplementary Content, Table SII). Notably, alloimmunisation against antigens of the Rh and Kell systems accounted for 78% of the total cases. It should be noted that 9.4% of alloimmunised patients had antibodies directed against more than one RBC antigen (mostly, alloantibodies against antigens of the Rh and Kell systems). Four studies\(^{27,28,35,39\)) reported only the frequency per single antigen without a description of the presence of more than one antigen in the same subject.

The comparison of the prevalence of erythrocyte alloantibodies in patients with thalassaemia major (total 25 studies evaluated) and thalassaemia intermedia (total 8 studies evaluated) is presented in Figure 3 and Table II. In patients with thalassaemia major, Q was 212.1, \( \tau^2=0.4583, I^2 88.7\% \), whereas in those with thalassaemia intermedia, Q was 24.59, \( \tau^2=0.4134, I^2 71.5\% \). In the aggregate set of patients with either thalassaemia major or thalassaemia intermedia, Q was 239.1, \( \tau^2=0.4437, I^2 86.6\% \). The results of the test for subgroup differences (random effects model) were: Q=1.95, d.o.f.=1, p=0.1629 (not significant). Thus, the prevalence of alloantibodies in thalassaemia major and thalassaemia intermedia did not appear to differ significantly. The rate of erythrocyte alloimmunisation in patients with thalassaemia major ranged from 2.7% (Bhava et al.\(^{49}\)) to 30.0% (Ameen et al.\(^{11}\)) and from 0% (Dogra et al.\(^{40}\)) to 38.1% (Saied et al.\(^{27}\)) in patients with thalassaemia intermedia (Online Supplementary Table SIV).

Table I - Characteristics and main results of the studies included on alloimmunisation in transfusion-dependent thalassaemia. (continued from previous page)

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Origin</th>
<th>Study design</th>
<th>Cases (N)</th>
<th>Median age, years (range)</th>
<th>Type (a/b)</th>
<th>Alloantibodies</th>
<th>Transfusion policy</th>
<th>Risk factors analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhava (2017)</td>
<td>49</td>
<td>India</td>
<td>Cohort, prospective</td>
<td>250 TM</td>
<td>NA (1-80)</td>
<td>8/250 (3.2)</td>
<td>Anti-K (50); anti-D (25); anti-E (12.5); anti-Kpa (12.5)</td>
<td>Non-leucoreduced RBC.</td>
<td>-</td>
</tr>
<tr>
<td>Davoudi-Kiakalayeh (2017)</td>
<td>50</td>
<td>Iran</td>
<td>Cohort, retrospective</td>
<td>190 TM</td>
<td>26 (+5.9)</td>
<td>47/190 (24.7)</td>
<td>Anti-K (33); anti-E (25); anti-D (19)</td>
<td>Post-storage leucoreduced RBC.</td>
<td>-</td>
</tr>
<tr>
<td>Alkindi (2017)</td>
<td>51</td>
<td>Oman</td>
<td>Cohort, prospective</td>
<td>129 TM</td>
<td>NA (5-32)</td>
<td>26/129 (20)</td>
<td>Anti-K (26.9); anti-E (23.1); anti-C (7.7); anti-C+anti-D (7.7); anti-D (3.8); anti-e (3.8); anti-Kpa (3.8); anti-E+anti-K (3.8); anti-C+anti-e (3.8); anti-C+anti-D+anti-Jka (3.8); anti-E-anti-Cw (3.8)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Al-Riyami (2018)</td>
<td>52</td>
<td>Oman</td>
<td>Cohort, retrospective</td>
<td>268 TDT</td>
<td>22 (2-43)</td>
<td>25/268 (9.3)</td>
<td>Anti-E (24); anti-K (24); anti-D (12); anti-c (12); anti-C (12); anti-e (8); anti-Kpa (8)</td>
<td>Extended phenotype-matched RBC. Leucoreduced RBC.</td>
<td>-</td>
</tr>
<tr>
<td>Moeen (2018)</td>
<td>53</td>
<td>Pakistan</td>
<td>Cohort, cross-sectional</td>
<td>302 TM</td>
<td>NA</td>
<td>12/302 (4.0)</td>
<td>Anti-Cw (33); anti-K (17); anti-k (17); anti-S (17); anti-Lua (17)</td>
<td>Non leucoreduced RBC.</td>
<td>-</td>
</tr>
</tbody>
</table>
that emerged from the analysis of the studies included (Table II) were: age\textsuperscript{25,27,29,52}, female gender\textsuperscript{19,34,48}, splenectomy\textsuperscript{13,20,26,29,35,42,48}, first transfusion before 2-3 years of age\textsuperscript{22,33,37,48}, and RBC units received/duration of blood transfusion/transfusion frequency\textsuperscript{18,26,27,29,35,36,52}. By contrast, increased antigen matching for Rh and Kell and the use of leucoreduced RBC were found to have a protective effect against alloantibody development\textsuperscript{13,14,25,27,35,43,45,47}.

A meta-analytical approach to weigh the risk of RBC alloimmunisation associated with each factor was not possible because of the clinical heterogeneity and inconsistency of reporting among the different studies.

Figure 2 - Forest plot of the prevalence of red blood cell alloantibodies in patients with thalassaemia.

CI: confidence intervals.

Table II - Comparison of the prevalence of erythrocyte alloimmunisation between patients with thalassaemia major and thalassaemia intermedia.

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Model</th>
<th>N. of studies</th>
<th>Mean proportion</th>
<th>95% C.I.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TM</td>
<td>Random effects</td>
<td>25</td>
<td>0.1012</td>
<td>0.0773</td>
</tr>
<tr>
<td>TI</td>
<td>Random effects</td>
<td>8</td>
<td>0.1497</td>
<td>0.0918</td>
</tr>
<tr>
<td>All</td>
<td>Random effects</td>
<td>33</td>
<td>0.1100</td>
<td>0.0871</td>
</tr>
</tbody>
</table>

Studies distinguishing the clinical variants, thalassaemia major (TM) and thalassaemia intermedia (TI). The mean proportion (prevalence) of alloantibodies is reported for patients with TM and TI with 95% confidence intervals (C.I.). The same indexes are reported on the aggregate (all) set of studies.
or simply by chance. In the current systematic review, the statistical heterogeneity was substantial; this was addressed by using a random effects model. A random effects model allows more flexibility, assuming that there may be other factors influencing the data than error or chance, within and between studies. Beside the statistical heterogeneity, there was clinical and methodological heterogeneity in the studies included in the review. Differences in study designs and methodological quality (risk of bias) represent methodological heterogeneity. All the studies included in this review were classified as cohort studies, although the design of the studies varied. There were prospective, retrospective and cross-sectional cohorts. However, our assessment of bias using the NOS shows that the quality of the included studies was high. There was

Discussion

To our knowledge, this is the first published systematic review on the prevalence of RBC alloimmunisation in patients with transfusion-dependent thalassaemia. After the identification of 41 eligible cohort studies involving 9,256 thalassaemia patients, we determined a prevalence of erythrocyte alloimmunisation of 11.4%. The wide variation in the rate of RBC alloimmunisation (2.9 to 37%) observed among the different studies probably reflects the heterogeneity of the studies, which is common in reviews addressing prevalence and incidence data. There are three types of heterogeneity: clinical, methodological, and statistical\(^7\). Statistical heterogeneity is the variation of effect sizes between studies. Statistical heterogeneity may arise because of clinical heterogeneity, methodological heterogeneity, or simply by chance. In the current systematic review, the statistical heterogeneity was substantial; this was addressed by using a random effects model. A random effects model allows more flexibility, assuming that there may be other factors influencing the data than error or chance, within and between studies. Beside the statistical heterogeneity, there was clinical and methodological heterogeneity in the studies included in the review. Differences in study designs and methodological quality (risk of bias) represent methodological heterogeneity. All the studies included in this review were classified as cohort studies, although the design of the studies varied. There were prospective, retrospective and cross-sectional cohorts. However, our assessment of bias using the NOS shows that the quality of the included studies was high. There was
also clinical heterogeneity in the studies considered in the analysis related to specific covariates (e.g., age, gender, ethnicity), transfusion policy (including the use of non-leucoreduced RBC units and the degree of antigen-matching techniques), different methods of antibody identification, and heterogeneity of the donor and the recipient populations. Unfortunately, due to limitations and inconsistencies in reporting alloantibody prevalences according to these covariates, we could not perform subgroup analyses or meta-regressions for all the relevant covariates. However, our subgroup analysis of clinical variants showed that the prevalences of alloantibodies in thalassaemia major and thalassaemia intermedia did not differ significantly.

It has been consistently reported that the ethnic correlation between donors and recipients influences the frequency of erythrocyte alloimmunisation in both thalassaemia and sickle cell anaemia patients. Lower rates of RBC alloimmunisation were reported in studies with more homogeneous donor and patient populations, while higher rates were observed in studies with ethnic/racial disparity between donors and recipients. For example, in the study by Abdelrazik and colleagues, the relatively low rate of alloimmunisation (8%) was attributed to the fact that blood donors and thalassaemic patients were from the same ethnic Egyptian group.

Among the other risk factors associated with RBC alloimmunisation in patients with transfusion-dependent thalassaemia, splenectomy was that most frequently reported. For instance, Singer and colleagues reported that patients who underwent splenectomy had a higher rate of alloimmunisation compared to non-splenectomised patients. In multivariate analysis, Thompson and co-workers found that splenectomy was an independent risk factor for alloimmunisation. The mechanism by which removal of the spleen increases alloantibody formation is unclear. One possible explanation is that the absence of the spleen may further enhance the immune response to infused foreign blood antigens that are not effectively filtered. Other studies, however, did not find such an association. In any case, although frequently performed in the past, the currently lower tendency to perform splenectomy in transfusion-dependent thalassaemia patients might mitigate such risk.

Other important risk factors for RBC alloimmunisation that emerged from our systematic analysis of the literature were the duration of transfusions and the age at the start of transfusion therapy, with older patients being at increased risk. While the former finding is obviously related to the amount of exposure to RBC antigens during the years of blood transfusions, the latter is quite intriguing. Some authors have in fact reported a lower rate of alloimmunisation in patients who began transfusion before 2-3 years of age. The still immature immune system of young patients could be responsible for a lower risk of alloimmunisation by creating a kind of immunotolerance. While the early institution of transfusion therapy after diagnosis could be an interesting approach to minimise the risk of alloimmunisation risk, on the other hand it could expose patients with thalassaemia to an increased risk of other transfusion-related complications.

An unresolved issue regards the different risk of RBC alloimmunisation in transfusion-dependent patients with thalassaemia major or thalassaemia intermedia. Various studies found a higher percentage of RBC alloantibodies among patients with thalassaemia intermedia than among those with thalassaemia major. The results of our systematic review confirm this trend (Table II): although the difference was not statistically significant, we observed a higher prevalence of alloantibodies in patients with thalassaemia intermedia. While patients with thalassaemia major usually start RBC transfusions earlier than patients with thalassaemia intermedia and thus could benefit from the protective effect of the younger age reported above, this finding could also reflect differences in transfusion policies between the two types of thalassaemia. Indeed, it is conceivable that patients with thalassaemia intermedia, having lower and less regular transfusion requirements, could be transfused more frequently with non-extended phenotype matched RBC units than are patients with thalassaemia major. On the other hand, the large differences in sample sizes among the two cohorts of patients evaluated (4,829 patients with thalassaemia major vs 491 patients with thalassaemia intermedia) could represent an important bias for the subgroup analysis of the results.

No definitive association between female gender and alloimmunisation risk could be found because of the conflicting results reported from the different studies included in this systematic analysis.

Finally, in this systematic review the most frequent antibodies identified in patients with transfusion-dependent thalassaemia were directed against Rh and Kell systems, accounting for 78% of all cases. This means that matching RBC units for these antigens will reduce the risk of RBC alloimmunisation by about 80% in such patients. With the aim of risk minimisation, we therefore recommend, in accordance with the main standard guidelines, the implementation of an early diagnosis of thalassaemia with the determination of baseline extended RBC phenotype and the provision of RBC units matched for Rh and Kell antigens.

**Acknowledgements**

The Authors thank Professor Marilyn Scopes.
(Italian Foundation for Research on Anaemia and Haemoglobinopathies, Genoa, Italy) for her precious assistance with the English editing that greatly improved this manuscript.

Disclosure of conflicts of interest
Giancarlo M. Liumbruno is the Editor-in-Chief of Blood Transfusion. As a result, this manuscript was subjected to an additional external review. The Authors declare no conflicts of interest.

References
Red blood cell alloantibodies in thalassaemia


